Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems.
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned stakeholders. In part this is due to the fact that the pharmaceutical industry now accrues ~25% of its annual revenues from DRPx products.
The past few years have seen the emergence of a number of new technologies. Some of these advances will have a significant effect on the nature of medicines and the way in which they are developed. This article discusses some of the significant changes in the regulatory oversight of drug development and licensing.
Over the past several years, there has been continuing interest in the deployment of personalised medicine via the development of companion diagnostics/therapeutics. The leading edge of this discipline is in the cancer personalised medicine arena where a number of therapeutics are associated with a diagnostic entity that serves to stratify those patient populations who can benefit from the given therapeutic.